vs
CSP INC（CSPI）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
CSP INC的季度营收约是Protalix BioTherapeutics, Inc.的1.3倍（$12.0M vs $9.1M），CSP INC净利率更高（0.8% vs -60.3%，领先61.1%），CSP INC同比增速更快（-23.2% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-3.0M），过去两年CSP INC的营收复合增速更高（-6.3% vs -6.7%）
CSP Inc.是一家总部位于美国的科技企业，主营网络安全解决方案、托管IT服务、高性能计算系统及专业IT咨询服务，核心客户覆盖北美及部分国际市场的医疗、金融、制造、公共部门等领域的企业。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CSPI vs PLX — 直观对比
营收规模更大
CSPI
是对方的1.3倍
$9.1M
营收增速更快
CSPI
高出26.7%
-49.9%
净利率更高
CSPI
高出61.1%
-60.3%
自由现金流更多
PLX
多$4.6M
$-3.0M
两年增速更快
CSPI
近两年复合增速
-6.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.0M | $9.1M |
| 净利润 | $91.0K | $-5.5M |
| 毛利率 | 39.3% | 49.4% |
| 营业利润率 | -0.9% | -51.1% |
| 净利率 | 0.8% | -60.3% |
| 营收同比 | -23.2% | -49.9% |
| 净利润同比 | -80.7% | -184.8% |
| 每股收益（稀释后） | $0.01 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSPIPLX
| Q4 25 | $12.0M | $9.1M | ||
| Q3 25 | $14.5M | $17.9M | ||
| Q2 25 | $15.4M | $15.7M | ||
| Q1 25 | $13.1M | $10.1M | ||
| Q4 24 | $15.7M | $18.2M | ||
| Q3 24 | $13.0M | $18.0M | ||
| Q2 24 | $13.1M | $13.5M | ||
| Q1 24 | $13.7M | — |
净利润CSPIPLX
| Q4 25 | $91.0K | $-5.5M | ||
| Q3 25 | $-191.0K | $2.4M | ||
| Q2 25 | $-264.0K | $164.0K | ||
| Q1 25 | $-108.0K | $-3.6M | ||
| Q4 24 | $472.0K | $6.5M | ||
| Q3 24 | $-1.7M | $3.2M | ||
| Q2 24 | $-185.0K | $-2.2M | ||
| Q1 24 | $1.6M | — |
毛利率CSPIPLX
| Q4 25 | 39.3% | 49.4% | ||
| Q3 25 | 36.6% | 53.4% | ||
| Q2 25 | 28.8% | 62.5% | ||
| Q1 25 | 32.0% | 19.1% | ||
| Q4 24 | 29.1% | 78.7% | ||
| Q3 24 | 28.4% | 53.4% | ||
| Q2 24 | 35.0% | 29.8% | ||
| Q1 24 | 47.3% | — |
营业利润率CSPIPLX
| Q4 25 | -0.9% | -51.1% | ||
| Q3 25 | -3.7% | 11.9% | ||
| Q2 25 | -7.9% | 7.5% | ||
| Q1 25 | -7.6% | -41.0% | ||
| Q4 24 | -2.3% | 39.6% | ||
| Q3 24 | -15.7% | 22.2% | ||
| Q2 24 | -5.5% | -18.0% | ||
| Q1 24 | 9.0% | — |
净利率CSPIPLX
| Q4 25 | 0.8% | -60.3% | ||
| Q3 25 | -1.3% | 13.2% | ||
| Q2 25 | -1.7% | 1.0% | ||
| Q1 25 | -0.8% | -35.8% | ||
| Q4 24 | 3.0% | 35.6% | ||
| Q3 24 | -12.7% | 18.0% | ||
| Q2 24 | -1.4% | -16.4% | ||
| Q1 24 | 11.6% | — |
每股收益（稀释后）CSPIPLX
| Q4 25 | $0.01 | $-0.06 | ||
| Q3 25 | $-0.02 | $0.03 | ||
| Q2 25 | $-0.03 | $0.00 | ||
| Q1 25 | $-0.01 | $-0.05 | ||
| Q4 24 | $0.05 | $0.10 | ||
| Q3 24 | $-0.17 | $0.03 | ||
| Q2 24 | $-0.02 | $-0.03 | ||
| Q1 24 | $0.16 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.9M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.8M | $48.2M |
| 总资产 | $69.2M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSPIPLX
| Q4 25 | $24.9M | $14.7M | ||
| Q3 25 | $27.4M | $13.6M | ||
| Q2 25 | $26.3M | $17.9M | ||
| Q1 25 | $29.5M | $19.5M | ||
| Q4 24 | $30.7M | $19.8M | ||
| Q3 24 | $30.6M | $27.4M | ||
| Q2 24 | $28.9M | $23.4M | ||
| Q1 24 | $27.1M | — |
股东权益CSPIPLX
| Q4 25 | $44.8M | $48.2M | ||
| Q3 25 | $44.6M | $52.9M | ||
| Q2 25 | $47.5M | $49.9M | ||
| Q1 25 | $47.5M | $45.2M | ||
| Q4 24 | $47.5M | $43.2M | ||
| Q3 24 | $47.3M | $32.4M | ||
| Q2 24 | $48.1M | $28.6M | ||
| Q1 24 | $48.2M | — |
总资产CSPIPLX
| Q4 25 | $69.2M | $82.3M | ||
| Q3 25 | $71.2M | $82.3M | ||
| Q2 25 | $66.8M | $78.5M | ||
| Q1 25 | $67.1M | $73.9M | ||
| Q4 24 | $67.5M | $73.4M | ||
| Q3 24 | $69.4M | $61.6M | ||
| Q2 24 | $66.8M | $91.5M | ||
| Q1 24 | $64.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $1.6M |
| 自由现金流率自由现金流/营收 | -25.1% | 17.8% |
| 资本支出强度资本支出/营收 | 0.9% | 4.4% |
| 现金转化率经营现金流/净利润 | -32.04× | — |
| 过去12个月自由现金流最近4个季度 | $-2.8M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CSPIPLX
| Q4 25 | $-2.9M | $2.0M | ||
| Q3 25 | $1.9M | $-3.7M | ||
| Q2 25 | $-3.3M | $-5.2M | ||
| Q1 25 | $1.9M | $-5.1M | ||
| Q4 24 | $1.7M | $4.0M | ||
| Q3 24 | $-1.5M | $4.1M | ||
| Q2 24 | $2.4M | $-3.6M | ||
| Q1 24 | $1.7M | — |
自由现金流CSPIPLX
| Q4 25 | $-3.0M | $1.6M | ||
| Q3 25 | $1.7M | $-4.2M | ||
| Q2 25 | $-3.3M | $-5.7M | ||
| Q1 25 | $1.9M | $-5.4M | ||
| Q4 24 | $1.7M | $3.6M | ||
| Q3 24 | $-1.5M | $4.0M | ||
| Q2 24 | $2.4M | $-3.8M | ||
| Q1 24 | $1.6M | — |
自由现金流率CSPIPLX
| Q4 25 | -25.1% | 17.8% | ||
| Q3 25 | 11.5% | -23.7% | ||
| Q2 25 | -21.7% | -36.2% | ||
| Q1 25 | 14.5% | -53.0% | ||
| Q4 24 | 10.8% | 19.6% | ||
| Q3 24 | -11.7% | 22.4% | ||
| Q2 24 | 17.9% | -28.1% | ||
| Q1 24 | 11.9% | — |
资本支出强度CSPIPLX
| Q4 25 | 0.9% | 4.4% | ||
| Q3 25 | 1.6% | 2.8% | ||
| Q2 25 | 0.4% | 2.8% | ||
| Q1 25 | 0.1% | 3.0% | ||
| Q4 24 | 0.3% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.3% | 1.3% | ||
| Q1 24 | 0.1% | — |
现金转化率CSPIPLX
| Q4 25 | -32.04× | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.69× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
